The main priority of the strategy is the use of international best practices, standards and scientific experience in the field of biomedicine, gene diagnostics and personalized selection of pharmacotherapy. Sistema-BioTech focuses its scientific activities on the most demanded areas of medicine — oncology, cardiology, reproductive medicine, neurology and severe congenital diseases.
The strategic goal of the company is setting up a biotechnological laboratory with a full cycle of research activities, ranging from gene sequencing to the creation of an active molecule, and further development of biotechnological products in the most demanded areas of medicine and pharmacology.
The company was founded in 2018, and by the end of 2020 it had already brought 6 scientific and practical developments to the Russian market. The main ones were test systems for the early diagnosis of the new coronavirus infection. To date, we have launched 9 portfolio products and more than 5 million tests.
The shareholders of Sistema-BioTech LLC are the Medsi network of medical clinics and Sistema Telecom Finance CJSC.
Sistema- BioTech LLC is a scientific and research laboratory created for the search and implementation of innovative medical and biological solutions in healthcare practice.